CytRx (NASDAQ: CYTR) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
This table compares CytRx and BeyondSpring’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for CytRx and BeyondSpring, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CytRx presently has a consensus target price of $24.00, suggesting a potential upside of 1,255.93%. BeyondSpring has a consensus target price of $54.50, suggesting a potential upside of 104.12%. Given CytRx’s higher probable upside, equities research analysts clearly believe CytRx is more favorable than BeyondSpring.
Valuation and Earnings
This table compares CytRx and BeyondSpring’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
BeyondSpring has lower revenue, but higher earnings than CytRx.
Insider & Institutional Ownership
6.2% of CytRx shares are owned by institutional investors. Comparatively, 1.2% of BeyondSpring shares are owned by institutional investors. 5.3% of CytRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CytRx Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
BeyondSpring Company Profile
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.